DOG1 and PKC-are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors

Modern Pathology

Volumn 24, Issue 6, 2011, Pages 866-875

  Kang, Gu Hyun ^a   Srivastava, Amitabh ^b   Kim, Young Eun ^a   Park, Hee Jung ^a   Park, Cheol Keun ^a   Sohn, Tae Sung ^a   Kim, Sung ^a   Kang, Dae Young ^c   Kim, Kyoung Mee ^a  

^a Samsung Medical Center   (South Korea)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c Chungnam National University   (South Korea)

Author keywords

diagnosis; DOG1; gastrointestinal stromal tumor; KIT; PKC ; therapy

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN DOG 1; PROTEIN KINASE C THETA; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; ANO1 PROTEIN, HUMAN; ISOENZYME; MEMBRANE PROTEIN; PRKCQ PROTEIN, HUMAN; PROTEIN KINASE C; TUMOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXON; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIAGNOSIS; ADULT; AGED; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; STOMACH TUMOR;

ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-KIT; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79957917277     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.11     Document Type: Article

References (32)

1. Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004;202:430-438. (Pubitemid 38456161)
2. Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch 2010;456: 111-127.
3. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28: 889-894. (Pubitemid 38856844)
4. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. (Pubitemid 40023952)
5. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol 2009;33: 1401-1408.
6. Pauls K, Merkelbach-Bruse S, Thal D, et al. PDGFRal-pha-and c-kit-mutated gastrointestinal stromal tumours (GISTs) are characterized by distinctive histological and immunohistochemical features. His-topathology 2005;46:166-175. (Pubitemid 40293015)
7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465. (Pubitemid 34747864)
8. Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009;33: 437-446.
9. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22: 3813-3825. (Pubitemid 41095223)
10. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349. (Pubitemid 46621810)
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-480. (Pubitemid 34879334)
12. Wardelmann E, Buttner R, Merkelbach-Bruse S, et al. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451:743-749. (Pubitemid 47497944)
13. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338. (Pubitemid 44528723)
14. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastro-enterology 2005;128:270-279. (Pubitemid 40431080)
15. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-113. (Pubitemid 38821818)
16. Katoh M, Katoh M. FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products. Int J Oncol 2003;22:1375-1381.
17. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008;32:210-218. (Pubitemid 351172135)
18. Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004;64:5127-5131. (Pubitemid 39006529)
19. Kim KM, Kang DW, Moon WS, et al. PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol 2006;19:1480-1486. (Pubitemid 44624168)
20. Motegi A, Sakurai S, Nakayama H, et al. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005;55: 106-112. (Pubitemid 40477221)
21. Lee HE, Kim MA, Lee HS, et al. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostain-ing. J Clin Pathol 2008;61:722-729. (Pubitemid 351859964)
22. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117: 188-193. (Pubitemid 34823657)
23. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83. (Pubitemid 44692418)
24. Wardelmann E, Neidt I, Bierhoff E, et al. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod Pathol 2002;15: 125-136. (Pubitemid 34171322)
25. Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-495. (Pubitemid 34747867)
26. Lopes LF, West RB, Bacchi LM, et al. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol 2010;18:333-337.
27. Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med 2010;14:42-50.
28. Kang GH, Kim KM, Park CK, et al. PKC-theta expression in Ewing sarcoma/primitive neuroectodermal tumour and malignant peripheral nerve sheath tumour. Histopathology 2009;55:368-369.
29. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-695. (Pubitemid 38326618)
30. Miselli F, Millefanti C, Conca E, et al. PDGFRA immunostaining can help in the diagnosis of gastrointestinal stromal tumors. Am J Surg Pathol 2008;32: 738-743. (Pubitemid 351600827)
31. Agaimy A, Hartmann A. Hereditary and non-hereditary syndromic gastointestinal stromal tumours. Pathologe 2010;31:430-437.
32. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-5364. (Pubitemid 46206989)